News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Atilla Soran, MD, MPH

Articles by Atilla Soran, MD, MPH

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

ByLeslie Elmore,Neil Carleton,Michael S. Cowher,Rohit Bhargava,Emilia Diego,Kristin Lupinacci,Meaghan Marley,Qurat Ul Ain Sabih,Atilla Soran, MD, MPH,Jennifer Steiman,Ronald Johnson,Erin Bayley,Priscilla F. Mcauliffe, MD, PhD

May 17th 2025

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

ByAtilla Soran, MD, MPH,Kazim Senol,Schlomo Schneebaum,Shigeru Imoto,Carole Mathelin,Alexander Mundinger,Meltem Selam,Vahit Ozmen

April 21st 2025

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

ByZeynep Ozlem Soran,Allison Brophy,Lily Kass,Berkay Demirors,Hayeon Kim,Atilla Soran, MD, MPH,John Austin Vargo,Parul Barry

April 20th 2025

43 Factors Affecting Survival in Solitary Bone-Only De Novo Stage IV Metastatic Breast Cancer

ByKazim Senol,Aykut Soyder,Ahmet Dag,Didem Can Trabulus,Ahmet Bilici,Mutlu Dogan,Hasan Karanlık,Serdar Ozbas,Atilla Soran, MD, MPH

April 26th 2023

43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms

ByAtilla Soran, MD, MPH,Fuat B. Bengur,Wendy Rodriguez,Efe Sezgin

May 6th 2022

Lymphedema Prevention and Early Intervention: A Worthy Goal

ByAtilla Soran, MD, MPH,David N. Finegold, MD,Adam M. Brufsky, MD, PhD

March 12th 2012

The etiology and risk factors of breast cancer–related lymphedema (BCRL) are multifactorial and not fully understood.

Latest Updated Articles

Lymphedema Prevention and Early Intervention: A Worthy Goal
Published: March 12th 2012 | Updated:

Trending on CancerNetwork

Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL

Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer

3 Things You Should Know About Future Directions for BsAbs and ADCs in NSCLC

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Axi-cel Produces Enduring Real-World Responses in R/R Follicular Lymphoma

© 2025 MJH Life Sciences^®

All rights reserved.